Juan Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Juan Jin has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Xiao-Ming Meng
Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China
13 shared publications Hang Yang
School of Basic Medicine, School of Pharmacy Anhui Medical University Hefei China
4 shared publicationsHe-Ge Bian
School of Basic Medicine, Anhui Medical University, Hefei 230032, China
4 shared publicationsJia-Nan Wang
Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, The Key Laboratory of Anti-inflammatory of Immune Medicines, Ministry of Education, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
4 shared publicationsJie Ying
School of Basic Medicine, School of Pharmacy Anhui Medical University Hefei China
4 shared publicationsTong Zu
School of Basic Medicine, School of Pharmacy Anhui Medical University Hefei China
4 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Fumarate-induced succination of A-kinase anchor protein 12 exacerbates renal inflammation and fibrosis
The inflammatory response resulting from the abnormal accumulation of metabolites has been implicated in the pathogenesis of organ fibrosis; however, its role and underlying mechanisms in renal fibrosis remain unclear. In this study, we observed a negative correlation between fumarate hydratase (FH) expression and the degree of renal fibrosis. Loss of FH function was associated with heightened inflammation and exacerbated tubulointerstitial damage in the kidney. Moreover, FH deficiency aggravated fibrosis in both the liver and lungs. Mechanistically, the depletion of FH in renal tubular cells led to fumarate accumulation. Fumarate directly succinated A-kinase anchoring protein 12 at cysteine 670, thereby diminishing its capacity to inhibit the activity of protein kinase Cζ (PKCζ). This process exacerbated renal inflammation and fibrosis by activating the downstream PKCζ/NF-κB and PKCζ/β-catenin pathways. Additionally, the upregulation of FH through adeno-associated virus 2/9-mediated FH overexpression markedly mitigated renal inflammation and fibrosis. These findings highlighted the important role of fumarate accumulation in the advancement of renal fibrosis, supporting FH as a potential therapeutic target in renal fibrosis.
- 30 June 2026
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 136 (14)
Open AccessFumarate-induced succination of A-kinase anchor protein 12 exacerbates renal inflammation and fibrosis
The inflammatory response resulting from the abnormal accumulation of metabolites has been implicated in the pathogenesis of organ fibrosis; however, its role and underlying mechanisms in renal fibrosis remain unclear. In this study, we observed a negative correlation between fumarate hydratase (FH) expression and the degree of renal fibrosis. Loss of FH function was associated with heightened inflammation and exacerbated tubulointerstitial damage in the kidney. Moreover, FH deficiency aggravated fibrosis in both the liver and lungs. Mechanistically, the depletion of FH in renal tubular cells led to fumarate accumulation. Fumarate directly succinated A-kinase anchoring protein 12 at cysteine 670, thereby diminishing its capacity to inhibit the activity of protein kinase Cζ (PKCζ). This process exacerbated renal inflammation and fibrosis by activating the downstream PKCζ/NF-κB and PKCζ/β-catenin pathways. Additionally, the upregulation of FH through adeno-associated virus 2/9-mediated FH overexpression markedly mitigated renal inflammation and fibrosis. These findings highlighted the important role of fumarate accumulation in the advancement of renal fibrosis, supporting FH as a potential therapeutic target in renal fibrosis.
- Open Access
- 21 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (34) , e21459
NSUN5 Attenuates Renal Injury and Ferroptosis in Hyperuricaemic Nephropathy Through YBX2‐Dependent Stabilisation of SCD1 m5C Methylation
RNA 5‐methylcytosine (m5C) modification plays a critical role in multiple diseases; however, its function in hyperuricaemic nephropathy (HN) remains unclear. Here, we show that renal m5C levels are markedly decreased and the m5C methyltransferase NOP2/Sun RNA methyltransferase 5 (NSUN5) is downregulated in HN mice. Conditional knock‐in (cKI) mice and mouse tubular epithelial cells overexpressing NSUN5 exhibit resistance to uric acid (UA), thereby alleviating kidney injury, inflammation, and fibrosis in HN. Bisulphite sequencing coupled with RNA sequencing identifies stearoyl‐CoA desaturase‐1 (SCD1) as a direct NSUN5 target and reveals the involvement of NSUN5 in ferroptosis regulation. Mechanistically, NSUN5 installs m5C on SCD1 mRNA. The m5C reader YBX2 binds to the modified transcript, prolonging the half‐life of SCD1 mRNA and enhancing its stability, thereby suppressing ferroptosis. Elevated SCD1 also inhibits NF‐κB p65 phosphorylation and nuclear translocation, dampens inflammatory responses and promotes ABCG2‐dependent UA excretion. Recombinant NSUN5 further ameliorates renal injury in HN. Our findings revealed a novel NSUN5‐mediated mechanism and highlight a potential therapeutic target for HN.
- 21 April 2026
- Published by Wiley in Advanced Science
- Vol. 13 (34) , e21459
Open AccessNSUN5 Attenuates Renal Injury and Ferroptosis in Hyperuricaemic Nephropathy Through YBX2‐Dependent Stabilisation of SCD1 m5C Methylation
RNA 5‐methylcytosine (m5C) modification plays a critical role in multiple diseases; however, its function in hyperuricaemic nephropathy (HN) remains unclear. Here, we show that renal m5C levels are markedly decreased and the m5C methyltransferase NOP2/Sun RNA methyltransferase 5 (NSUN5) is downregulated in HN mice. Conditional knock‐in (cKI) mice and mouse tubular epithelial cells overexpressing NSUN5 exhibit resistance to uric acid (UA), thereby alleviating kidney injury, inflammation, and fibrosis in HN. Bisulphite sequencing coupled with RNA sequencing identifies stearoyl‐CoA desaturase‐1 (SCD1) as a direct NSUN5 target and reveals the involvement of NSUN5 in ferroptosis regulation. Mechanistically, NSUN5 installs m5C on SCD1 mRNA. The m5C reader YBX2 binds to the modified transcript, prolonging the half‐life of SCD1 mRNA and enhancing its stability, thereby suppressing ferroptosis. Elevated SCD1 also inhibits NF‐κB p65 phosphorylation and nuclear translocation, dampens inflammatory responses and promotes ABCG2‐dependent UA excretion. Recombinant NSUN5 further ameliorates renal injury in HN. Our findings revealed a novel NSUN5‐mediated mechanism and highlight a potential therapeutic target for HN.
- Open Access
- 1 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Renal insulin-like growth factor binding-protein 7 is a critical promoter of progressive diabetic kidney disease
Renal tubulointerstitial abnormalities predict diabetic kidney disease (DKD) progression, and targeting them may prevent DKD. Insulin-like growth factor binding-protein 7 (IGFBP7) is expressed in renal tubular cells and is elevated in both blood and urine during the early stages of human diabetes, serving as a predictor of the rate of disease progression. We showed that tubule- and glomerular-specific IGFBP7 promotes DKD, with tubular-derived IGFBP7 disrupting the renal microenvironment. IGFBP7 impairs mitochondrial bioenergetics in tubular cells, causing lipid accumulation, cell cycle arrest, interstitial inflammation, fibrosis, and glomerulosclerosis. These findings were substantiated by transgenic overexpression and the specific deletion of IGFBP7 in type 1/2 DKD mice. Mechanistically, IGFBP7 interacts with STAT3, promoting its acetylation/dimerization and downregulating mitochondrial bioenergetics. Our study identified levomefolic acid as a novel inhibitor of IGFBP7 and demonstrated its efficacy in mitigating the progression of DKD. Here we showed IGFBP7 is a promising therapeutic target for DKD.
- 1 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessRenal insulin-like growth factor binding-protein 7 is a critical promoter of progressive diabetic kidney disease
Renal tubulointerstitial abnormalities predict diabetic kidney disease (DKD) progression, and targeting them may prevent DKD. Insulin-like growth factor binding-protein 7 (IGFBP7) is expressed in renal tubular cells and is elevated in both blood and urine during the early stages of human diabetes, serving as a predictor of the rate of disease progression. We showed that tubule- and glomerular-specific IGFBP7 promotes DKD, with tubular-derived IGFBP7 disrupting the renal microenvironment. IGFBP7 impairs mitochondrial bioenergetics in tubular cells, causing lipid accumulation, cell cycle arrest, interstitial inflammation, fibrosis, and glomerulosclerosis. These findings were substantiated by transgenic overexpression and the specific deletion of IGFBP7 in type 1/2 DKD mice. Mechanistically, IGFBP7 interacts with STAT3, promoting its acetylation/dimerization and downregulating mitochondrial bioenergetics. Our study identified levomefolic acid as a novel inhibitor of IGFBP7 and demonstrated its efficacy in mitigating the progression of DKD. Here we showed IGFBP7 is a promising therapeutic target for DKD.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eadv4810
METTL1-mediated m 7 G methylation of Sarm1 mRNA promotes macrophage inflammatory responses and multiple organ injury
RNA modifications regulate phenotype and function of macrophages by regulating RNA translation, splicing, and stability. However, the role of N 7 -methylguanosine (m 7 G) modification in macrophages and inflammation remains unexplored. In this study, we observed elevated levels of the methyltransferase METTL1 and m 7 G modifications in macrophages from mouse and human tissues during acute kidney injury (AKI). METTL1 deficiency in myeloid cells mitigated multiorgan inflammation induced by cecal ligation and puncture and renal ischemia/reperfusion. Genetic deletion of METTL1 inhibited macrophage proinflammatory responses. We identified internal Sarm1 messenger RNA (mRNA) as a target of m 7 G modification that controls macrophage metabolic reprogramming. METTL1 deficiency in macrophages inhibited metabolic reprogramming, which was reversed by SARM1 overexpression that induced NAD + decline. Pharmacologically, SA91-0178, a specific METTL1 inhibitor, effectively alleviated tissue injury during septic inflammation. Collectively, our findings suggest that m 7 G modification enhances the stability of Sarm1 mRNA, thereby resulting in NAD + imbalance in macrophages, indicating that METTL1 may serve as a potential therapeutic target for systemic inflammation.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eadv4810
METTL1-mediated m 7 G methylation of Sarm1 mRNA promotes macrophage inflammatory responses and multiple organ injury
RNA modifications regulate phenotype and function of macrophages by regulating RNA translation, splicing, and stability. However, the role of N 7 -methylguanosine (m 7 G) modification in macrophages and inflammation remains unexplored. In this study, we observed elevated levels of the methyltransferase METTL1 and m 7 G modifications in macrophages from mouse and human tissues during acute kidney injury (AKI). METTL1 deficiency in myeloid cells mitigated multiorgan inflammation induced by cecal ligation and puncture and renal ischemia/reperfusion. Genetic deletion of METTL1 inhibited macrophage proinflammatory responses. We identified internal Sarm1 messenger RNA (mRNA) as a target of m 7 G modification that controls macrophage metabolic reprogramming. METTL1 deficiency in macrophages inhibited metabolic reprogramming, which was reversed by SARM1 overexpression that induced NAD + decline. Pharmacologically, SA91-0178, a specific METTL1 inhibitor, effectively alleviated tissue injury during septic inflammation. Collectively, our findings suggest that m 7 G modification enhances the stability of Sarm1 mRNA, thereby resulting in NAD + imbalance in macrophages, indicating that METTL1 may serve as a potential therapeutic target for systemic inflammation.
- 8 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353, 120368
Atractylenolide III attenuates acute kidney injury through phosphorylation of PIK3CA: Functional activation and molecular interaction analysis
- 8 August 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 353, 120368
Atractylenolide III attenuates acute kidney injury through phosphorylation of PIK3CA: Functional activation and molecular interaction analysis
- Open Access
- 18 March 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (6) , e70468
Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2‐Dependent Mechanisms in Hyperuricemic Nephropathy
Hyperuricemia has been linked to kidney problems including hyperuricemic nephropathy (HN), which is characterised by inflammation and fibrosis in the kidneys. HN is frequently observed in patients with chronic gout. However, the causes of HN are not fully understood and effective treatments are limited. The status of RNA m6A, expression, and location of METTL3 in the kidney was evaluated in mice with HN. The mechanism of the METTL3‐associated ABCG2 downregulation was further studied in mTEC cells and a potassium oxazinate + adenine‐induced mice model and adeno‐associated virus 9 (AAV9)‐mediated METTL3 silencing mice. Expressions of ABCG2, α‐SMA, collagen‐1, TGF‐β1, IL‐1β, IL‐6, and TNF‐α were analysed using real‐time PCR and western blotting. Hyperuricemia led to elevated m6A levels and METTL3 expression in mouse kidneys. METTL3 was mainly located in mTEC cells. METTL3‐specific inhibitor STM2457 alleviated uric acid‐induced inflammatory and fibrotic responses in mTEC cells. Mechanistically, ABCG2 was identified as a target of METTL3 by RNA sequencing. The stability of ABCG2 was decreased through the binding of IGF2BP2 (insulin‐like growth factor 2 binding protein 2) to its m6A‐modified stop codon regions. Silencing or inhibition of METTL3 significantly reduced uric acid‐induced cell injury and increased ABCG2 expression, leading to uric acid excretion. In vivo data showed that AAV9‐mediated METTL3 silencing significantly alleviated renal dysfunction and fibrosis in HN mice. Our study provides the first evidence that METTL3 regulates uric acid excretion by controlling the m6A levels of ABCG2 through the binding of IGF2BP2, and inhibiting METTL3 can effectively alleviate kidney damage caused by hyperuricemia, showing potential as a therapy for HN.
- 18 March 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (6) , e70468
Open AccessInhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2‐Dependent Mechanisms in Hyperuricemic Nephropathy
Hyperuricemia has been linked to kidney problems including hyperuricemic nephropathy (HN), which is characterised by inflammation and fibrosis in the kidneys. HN is frequently observed in patients with chronic gout. However, the causes of HN are not fully understood and effective treatments are limited. The status of RNA m6A, expression, and location of METTL3 in the kidney was evaluated in mice with HN. The mechanism of the METTL3‐associated ABCG2 downregulation was further studied in mTEC cells and a potassium oxazinate + adenine‐induced mice model and adeno‐associated virus 9 (AAV9)‐mediated METTL3 silencing mice. Expressions of ABCG2, α‐SMA, collagen‐1, TGF‐β1, IL‐1β, IL‐6, and TNF‐α were analysed using real‐time PCR and western blotting. Hyperuricemia led to elevated m6A levels and METTL3 expression in mouse kidneys. METTL3 was mainly located in mTEC cells. METTL3‐specific inhibitor STM2457 alleviated uric acid‐induced inflammatory and fibrotic responses in mTEC cells. Mechanistically, ABCG2 was identified as a target of METTL3 by RNA sequencing. The stability of ABCG2 was decreased through the binding of IGF2BP2 (insulin‐like growth factor 2 binding protein 2) to its m6A‐modified stop codon regions. Silencing or inhibition of METTL3 significantly reduced uric acid‐induced cell injury and increased ABCG2 expression, leading to uric acid excretion. In vivo data showed that AAV9‐mediated METTL3 silencing significantly alleviated renal dysfunction and fibrosis in HN mice. Our study provides the first evidence that METTL3 regulates uric acid excretion by controlling the m6A levels of ABCG2 through the binding of IGF2BP2, and inhibiting METTL3 can effectively alleviate kidney damage caused by hyperuricemia, showing potential as a therapy for HN.
- Top Cited PapersOpen Access
- 24 December 2024
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 31 (3) , 1-15
Insights into renal damage in hyperuricemia: Focus on renal protection (Review)
The incidence of hyperuricemia has increased recently, posing a serious threat to public health. Hyperuricemia is associated with an increased risk of gout, chronic kidney disease (CKD), obesity, metabolic syndrome, type 2 diabetes mellitus, hypertension, hypertriglyceridaemia, metabolic dysfunction‑associated steatotic liver disease, acute kidney injury, coronary heart disease and cardiovascular disease (CVD). These diseases are commonly accompanied by varying degrees of kidney damage. A number of randomized controlled clinical trials have investigated the effectiveness of UA‑lowering therapies in preventing kidney disease progression. The present review provided fundamental insights into the pathogenesis, principles and therapeutic approaches for managing hyperuricemia in patients with aforementioned diseases and assesses the effect of uric acid‑lowering therapy on diabetic nephropathy, systemic lupus erythematosus, CKD, CVD and obesity progression.
- 24 December 2024
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 31 (3) , 1-15
Top Cited PapersOpen AccessInsights into renal damage in hyperuricemia: Focus on renal protection (Review)
The incidence of hyperuricemia has increased recently, posing a serious threat to public health. Hyperuricemia is associated with an increased risk of gout, chronic kidney disease (CKD), obesity, metabolic syndrome, type 2 diabetes mellitus, hypertension, hypertriglyceridaemia, metabolic dysfunction‑associated steatotic liver disease, acute kidney injury, coronary heart disease and cardiovascular disease (CVD). These diseases are commonly accompanied by varying degrees of kidney damage. A number of randomized controlled clinical trials have investigated the effectiveness of UA‑lowering therapies in preventing kidney disease progression. The present review provided fundamental insights into the pathogenesis, principles and therapeutic approaches for managing hyperuricemia in patients with aforementioned diseases and assesses the effect of uric acid‑lowering therapy on diabetic nephropathy, systemic lupus erythematosus, CKD, CVD and obesity progression.
- 25 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 139, 112745
Aurantiamide mitigates acute kidney injury by suppressing renal necroptosis and inflammation via GRPR-dependent mechanism
- 25 July 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 139, 112745
Aurantiamide mitigates acute kidney injury by suppressing renal necroptosis and inflammation via GRPR-dependent mechanism
- 18 February 2024
- Published by Elsevier in Pesticide Biochemistry and Physiology
- Vol. 200, 105831
Targeted inhibition of transforming growth factor-β type I receptor by AZ12601011 improves paraquat poisoning-induced multiple organ fibrosis
- 18 February 2024
- Published by Elsevier in Pesticide Biochemistry and Physiology
- Vol. 200, 105831
Targeted inhibition of transforming growth factor-β type I receptor by AZ12601011 improves paraquat poisoning-induced multiple organ fibrosis
- Open Access
- 19 December 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (4) , 2381
Correction: CircRNA circ_0013339 Regulates the Progression of Colorectal Cancer Through miR-136-5p/SOX9 Axis
- 19 December 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (4) , 2381
Open AccessCorrection: CircRNA circ_0013339 Regulates the Progression of Colorectal Cancer Through miR-136-5p/SOX9 Axis